GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-10-22| Trials & Approvals

Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate

by Rajaneesh K. Gopinath
Share To
On October 21st, Sio Gene Therapies Inc. made two major announcements featuring one of its lead gene therapy candidates. The New York-based company presented positive interim data for AXO-AAV-GM1, its AAV9-based gene therapy for GM1 gangliosidosis, at the ESGCT Virtual Congress 2021. On the same day, it also announced the FDA's Fast Track Designation granted for the drug.

GM1 gangliosidosis is a rare inherited disease with no FDA-approved treatments currently. Safety is a big concern in the field of AAV gene therapy and several promising endeavors have been shut down recently due to adverse events. However, AXO-AAV-GM1 has shown promising safety and efficacy in both the low-dose and high-dose cohorts.

"The results from the GM1 gangliosidosis program is one of the light bulb moments for me and I think this gene therapy could really make a difference," Pavan Cheruvu told GeneOnline. "With these important data in hand, we anticipate a meeting with the FDA in the first half of 2022 to discuss the next steps for clinical development for AXO-AAV-GM1."

GO Prime with only $1.49 now

LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top